Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Apertura Gene Therapy will provide Lexeo Therapeutics access to its IV, BBB-crossing TfR1 CapX AAV capsid for a program designed to treat Friedreich ataxia.Material DetailsContext by AI AnalystThis is an early-stage strategic partnership expanding Apertura’s licensing of its CNS-targeting AAV capsi…
LXEO - Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
NEW YORK, Sept. 23, 2026 // -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high…